RE:RE:New Press Release - Toronto Stock Exchange, Theratechnologies Inc., View From The C-SuiteWhat's that? The press release for results of Q2 inJuly started with this sentence:
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol https://www.theratech.com/news-releases/news-release-details/theratechnologies-reports-second-quarter-2023-financial-results
juniper88 wrote: Paul states at the end of the video that the new TH1902 trial protocol should be approved in the next 2 months.
This is absurd.